A Phase Ib Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) in Previously Treated Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary) ; Durvalumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms CAMILLA
- 26 Sep 2019 Planned End Date changed from 30 Mar 2020 to 30 Jun 2020.
- 26 Sep 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Jun 2020.
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.